- $3.61bn
- $11.03bn
- $6.22bn
U.S. STOCKS ON THE MOVE-Nvidia, Wayfair, Moderna
U.S. STOCKS ON THE MOVE-McDonald's, Olo, Eli Lilly
Organon & Co reports results for the quarter ended March 31 - Earnings Summary
Brief: Organon Q1 Adjusted EPS USD 1.02 Vs. IBES Estimate USD 0.9
Expects $6 Million Milestone Expense In Q1 2025
Brief: Health Canada Approves Nduvra (Tapinarof Cream)
Brief: European Medicines Agency (EMA) Validates Henlius And Organon Filing For Perjeta® (Pertuzumab) Biosimilar Candidate HLX11
Organon rises on Q4 profit beat
Organon & Co reports results for the quarter ended December 31 - Earnings Summary
U.S. RESEARCH ROUNDUP-AmEx, Elevance Health, SouthState
Brief: FDA Approves Vtama® Cream, 1% For The Treatment Of Atopic Dermatitis
Brief: FDA Approves Dermavant Science's Vtama For Topical Treatment Of Atopic Dermatitis In Adult & Pediatric Patients 2 Years & Older
Brief: Update On FDA Review Of VTAMA Cream 1% For Atopic Dermatitis In Adults And Children Aged 2 And Older
Organon & Co reports results for the quarter ended in September 30 - Earnings Summary
Brief: Organon Reports Results For The Third Quarter Ended Sept. 30, 2024
Brief: Organon Q3 Adjusted EPS USD 0.87 Vs. IBES Estimate USD 0.9
EU regulator reviews anti-baldness drugs over concerns of suicidal thoughts (updated)
On Sept 17, Co & Unit Entered Into Agreement And Plan Of Merger By Dermavant Sciences & Roivant Sciences
Court revives more than 500 lawsuits over Fosamax femur fracture risk